Related Experiment Video

Updated: Oct 2, 2025

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.0K

Cyclophosphamide for the Treatment of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposition

Sabaa Asif1, Sumbal Nasir Mahmood1, Kunwer Naveed Mukhtar2

  • 1Department of Nephrology, Ziauddin University Hospital, Karachi, Pakistan.

Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia
|March 1, 2022
PubMed

Insights

Monoclonal gammopathy of renal significance (MGRS) encompasses kidney-related disorders. A case of proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID) showed positive response to steroid and cyclophosphamide treatment.

Area of Science:

  • Nephrology
  • Hematology
  • Immunology

Background:

  • Monoclonal gammopathy of undetermined significance (MGUS) affects over 3% of individuals over 50 and can progress to lymphoproliferative disorders.
  • Monoclonal gammopathies associated with renal disorders are now termed monoclonal gammopathy of renal significance (MGRS).
  • MGRS includes conditions like monoclonal immunoglobulin deposition disease (MIDD) and proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID).

Observation:

  • PGNMID is characterized by membranoproliferative glomerulonephritis-like lesions and immunoglobulin deposition.
  • This condition has a poor prognosis, and optimal treatment strategies are still under investigation.
  • A case study involved an elderly male with a history of light chain deposition disease (a form of MIDD).

Findings:

  • The patient, initially lost to follow-up, later presented with PGNMID.
  • Treatment with a combination of steroid and cyclophosphamide was administered.
  • The patient demonstrated a positive response to the applied treatment regimen.

Implications:

  • This case highlights a potential therapeutic approach for PGNMID, a severe renal disorder.
  • Further research into MGRS and its subtypes is crucial for improving patient outcomes.
  • Early recognition and management of MGRS may prevent irreversible kidney damage.

More Related Videos

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.9K
Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells04:46

Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells

Published on: March 7, 2025

501

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
231
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
95
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.5K